In MM, a recent preclinical study has demonstrated a significant reduction in tumor burden following treatment with the anti-CSF1R antibody [212], suggesting that targeting macrophages, via CSF1R, in combination with standard therapies, may be a promising therapeutic strategy in MM. The gene discussed is CSF1R; the disease is Miyoshi myopathy.